Aura Biosciences Completes $40 Million Series D Financing

Aura Biosciences Completes $40 Million Series D Financing

Cambridge, MA — April 02, 2019 — Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that it closed a $40 million Series D financing. New investor Medicxi led the round, with current investors Advent Life Sciences, Arix Bioscience, Chiesi Ventures, Columbus Venture Partners, Lundbeckfonden Ventures and Ysios Capital also participating. The Company plans to use the proceeds from the Series D financing to support the late stage clinical development of their lead asset, light-activated AU-011, for the treatment of primary choroidal melanoma.

Pappas, Chiesi Venture Fund Joins Ranks of Pharma & VC Partnerships

 
Pappas, Chiesi Venture Fund Joins Ranks of Pharma & VC Partnerships

Art Pappas has overseen his own firm’s venture capital investments for 20 years. Now the veteran life sciences investor is adding on a new role, scoping out investment opportunities for a pharmaceutical company’s new venture fund.

Italian pharma Chiesi Group’s recently-launched Chiesi Ventures will focus on investing in companies developing treatments for rare and orphan diseases. The bulk of the money for investments will come from Chiesi, but the fund will be managed by Durham, NC-based A.M. Pappas & Associates, whose own investing unit, Pappas Ventures, has backed numerous companies that have found exits via acquisition or initial public offering.

Chiesi Launches Venture Capital Fund via Strategic Collaboration with A. M. Pappas & Associates

Chiesi Launches Venture Capital Fund via Strategic Collaboration with A. M. Pappas & Associates

Strategic Collaboration to Focus on Rare Disease Early Stage Investment Opportunities

PARMA, Italy and RESEARCH TRIANGLE PARK, North Carolina, September 2, 2014 /PRNewswire/ — The Chiesi Group announced today the launch of its venture capital fund, Chiesi Ventures, via a strategic collaboration with A. M. Pappas & Associates.

Chiesi Ventures will complement the strategic interest of the Chiesi Group in the area of rare diseases by investing in early stage opportunities and expanding the Chiesi network in the US among universities, venture capital investors, rare disease patient organizations and entrepreneurial companies developing treatments for rare diseases.